US Pharma MarketingAmgen, AbbVie say IRA negotiations impacted Q1 sales
Five months after the first drug prices negotiated under the Inflation Reduction Act took effect, at least two drugmakers — Amgen and AbbVie — say they’re feeling the impact. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure…
At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January.
Amgen and AbbVie reported in their first-quarter earnings ...
Source: Endpoints News